The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
ONLY
ARTICLE
April 5, 2021
Ripretinib (Qinlock) for GIST (online only)
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Ripretinib (Qinlock) for GIST (online only)
April 5, 2021 (Issue: 1621)
The FDA has approved the oral tyrosine kinase inhibitor
ripretinib (Qinlock – Deciphera) for treatment of adults
with advanced gastrointestinal stromal tumors (GISTs)
who have previously received treatment with ≥3 kinase
inhibitors,...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.